Vor Biopharma director granted 57,162 stock options

Vor Biopharma Inc. director Michel Detheux received a grant of stock options covering 57,162 shares of common stock.

Rhea-AI Filing Summary

Vor Biopharma Inc. director Michel Detheux received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. These are compensation-related awards, not open-market purchases.

One thirty-sixth of the option grant will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, conditioned on Detheux’s continued service. Following this award, he holds options for 57,162 shares directly according to this filing.

Insider Trade Summary

Grant/Award: 57,162 shares

Grant/Award 1 txn

Insider Detheux Michel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	57,162	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 57,162 contracts (Direct)

Footnotes (1)

1. F1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

Option grant size: 57,162 options Exercise price: $14.09 per share Expiration date: June 10, 2036 +3 more

6 metrics

Option grant size 57,162 options Stock option award to director Michel Detheux

Exercise price $14.09 per share Exercise price of granted stock options

Expiration date June 10, 2036 Option expiration for this grant

Underlying shares 57,162 shares Common stock underlying the option grant

Post-grant holdings 57,162 options Total options held following this transaction

Initial vesting date July 11, 2026 First one-thirty-sixth of options vests

Key Terms

Stock option (right to buy), exercise price, expiration date, Common stock, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 14.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Common stock financial

"underlying_security_title: Common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"shares subject to the option shall vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vor Biopharma (VOR) director Michel Detheux report on this Form 4?

Michel Detheux reported receiving a grant of stock options for 57,162 Vor Biopharma common shares. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price if they vest.

How many Vor Biopharma (VOR) shares are covered by Detheux’s new options?

The new stock option grant covers 57,162 shares of Vor Biopharma common stock. This figure matches both the derivative amount granted and Detheux’s total option holdings reported following the transaction in this Form 4 filing.

What is the exercise price and expiration date of Michel Detheux’s Vor Biopharma options?

Detheux’s options have an exercise price of $14.09 per share and expire on June 10, 2036. This means he can choose to buy shares at $14.09 any time after vesting and before the 2036 expiration date.

Is Michel Detheux’s Vor Biopharma Form 4 a stock purchase or a compensation grant?

The Form 4 reflects a compensation grant, not a market purchase. The transaction code “A” and description show it is a grant or award of stock options, giving Detheux the right to acquire shares in the future if vesting conditions are met.

How do Michel Detheux’s Vor Biopharma options vest over time?

One thirty-sixth of the 57,162 options will vest on July 11, 2026, with additional portions vesting monthly. Vesting continues each month as long as Detheux remains in service, gradually increasing the number of exercisable options he can use.

Did Michel Detheux sell any Vor Biopharma (VOR) shares in this Form 4?

The Form 4 shows no share sales or open-market trades. It records only a grant of stock options classified as an acquisition, with zero reported buy or sell transactions in the transaction summary for this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 08:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Detheux Michel

(Last) (First) (Middle)

500 BOYLSTON STREET, SUITE 1350

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$14.09	06/11/2026		A		57,162		(1)	06/10/2036	Common stock	57,162	$0	57,162	D

Explanation of Responses:

1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Adi Osovsky, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)